Takeda Reveals Phase III Results for Soticlestat (TAK-935) in Dravet and Lennox-Gastaut Syndromes
Takeda revealed topline results from its SKYLINE and SKYWAY studies. SKYLINE (TAK-935-3001) was a multicenter, randomized, double-blind Phase III trial assessing soticlestat (TAK-935) plus standard care against placebo plus standard care in patients with refractory Dravet syndrome. Soticlestat narrowly missed the primary endpoint of reducing convulsive seizure frequency from baseline compared to placebo (p-value = 0.06). However, in the six key secondary endpoints, soticlestat demonstrated clinically meaningful and nominally significant outcomes in the responder rate, ...